DeZwarteRidder schreef op 13 juli 2022 16:58:
Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment
Provided by Dow Jones
Jul 13, 2022 2:09 PM GMT+2
Shares of Humanigen Inc. (HGEN) plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.'s (GILD) Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen's stock is down 19.6% this year, while the S&P 500 has declined 19.9%.
-Jaimy Lee
(END) Dow Jones Newswires